Due to the minimal signs of anti-tumor activity (10.3% of participants had transient PSA decreases, including only 1 confirmed PSA50 response; 3 participants had partial response by PCWG3 criteria in the context of rapidly rising PSA) and high incidence of CRS, the study was terminated. The gene discussed is KLK3; the disease is neoplasm.